161 related articles for article (PubMed ID: 12398786)
41. Factors influencing the length of hospitalisation in intensive care units: a prospective observational study.
Vacca F; Vaiani M; Messori A; Trippoli S; Maltoni S; Pelaotti F; Santarlasci B; Bardelli F
Pharm World Sci; 2004 Oct; 26(5):263-7. PubMed ID: 15598066
[TBL] [Abstract][Full Text] [Related]
42. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis.
Wiedermann CJ; Kaneider NC
Blood Coagul Fibrinolysis; 2006 Oct; 17(7):521-6. PubMed ID: 16988545
[TBL] [Abstract][Full Text] [Related]
43. Antithrombotic therapies for sepsis: a need for more studies.
Minneci PC; Deans KJ; Cui X; Banks SM; Natanson C; Eichacker PQ
Crit Care Med; 2006 Feb; 34(2):538-41. PubMed ID: 16424739
[No Abstract] [Full Text] [Related]
44. Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction.
Inthorn D; Hoffmann JN; Hartl WH; Mühlbayer D; Jochum M
Shock; 1997 Nov; 8(5):328-34. PubMed ID: 9361342
[TBL] [Abstract][Full Text] [Related]
45. Antithrombin III and sepsis.
Mammen EF
Intensive Care Med; 1998 Jul; 24(7):649-50. PubMed ID: 9722032
[No Abstract] [Full Text] [Related]
46. Antithrombin III concentrates in intensive care.
Bernhardt W; Nováková-Banet A
Ric Clin Lab; 1983; 13(1):61-6. PubMed ID: 6344178
[TBL] [Abstract][Full Text] [Related]
47. Neonatal antithrombin III deficiency.
Manco-Johnson MJ
Am J Med; 1989 Sep; 87(3B):49S-52S. PubMed ID: 2679071
[TBL] [Abstract][Full Text] [Related]
48. [Antithrombin III in intensive therapy].
Baudo F; Caimi TM; Decataldo F; Calori G
Minerva Anestesiol; 1999; 65(1-2 Suppl 1):71-6. PubMed ID: 10206028
[No Abstract] [Full Text] [Related]
49. Low-dose immunoglobulin G is not associated with mortality in patients with sepsis and septic shock.
Iizuka Y; Sanui M; Sasabuchi Y; Lefor AK; Hayakawa M; Saito S; Uchino S; Yamakawa K; Kudo D; Takimoto K; Mayumi T; Azuhata T; Ito F; Yoshihiro S; Hayakawa K; Nakashima T; Ogura T; Noda E; Nakamura Y; Sekine R; Yoshikawa Y; Sekino M; Ueno K; Okuda Y; Watanabe M; Tampo A; Saito N; Kitai Y; Takahashi H; Kobayashi I; Kondo Y; Matsunaga W; Nachi S; Miike T; Takahashi H; Takauji S; Umakoshi K; Todaka T; Kodaira H; Andoh K; Kasai T; Iwashita Y; Arai H; Murata M; Yamane M; Shiga K; Hori N
Crit Care; 2017 Jul; 21(1):181. PubMed ID: 28701223
[TBL] [Abstract][Full Text] [Related]
50. [An experimental study on the protective effect of ATIII against acute disseminated intravascular coagulation].
Takei H
Nihon Ketsueki Gakkai Zasshi; 1986 Aug; 49(5):1081-90. PubMed ID: 3788435
[No Abstract] [Full Text] [Related]
51. Antithrombin III in patients with severe sepsis: a pharmacokinetic study.
Ilias W; List W; Decruyenaere J; Lignian H; Knaub S; Schindel F; Keinecke HO; Heinrichs H; Thijs LG
Intensive Care Med; 2000 Jun; 26(6):704-15. PubMed ID: 10945387
[TBL] [Abstract][Full Text] [Related]
52. [Current views on the therapeutic use of heparin and antithrombin III in disseminated intravascular coagulation].
Sobczyk J; Swietliński J; Podleśny-Owsińska T
Pol Tyg Lek; 1989 Oct 2-16; 44(40-42):896-8. PubMed ID: 2487947
[No Abstract] [Full Text] [Related]
53. Severe sepsis, coagulation, and fibrinolysis: dead end or one way?
Fourrier F
Crit Care Med; 2012 Sep; 40(9):2704-8. PubMed ID: 22732284
[TBL] [Abstract][Full Text] [Related]
54. First day dynamic changes in antithrombin III activity after supplementation have a predictive value in critically ill patients.
Gando S; Sawamura A; Hayakawa M; Hoshino H; Kubota N; Oshiro A
Am J Hematol; 2006 Dec; 81(12):907-14. PubMed ID: 16924643
[TBL] [Abstract][Full Text] [Related]
55. Is antithrombin III for sepsis-associated disseminated intravascular coagulation really ineffective?
Iba T; Thachil J
Intensive Care Med; 2016 Jul; 42(7):1193-4. PubMed ID: 27143022
[No Abstract] [Full Text] [Related]
56. Clinical trial results with antithrombin III in sepsis.
Fourrier F; Jourdain M; Tournoys A
Crit Care Med; 2000 Sep; 28(9 Suppl):S38-43. PubMed ID: 11007196
[TBL] [Abstract][Full Text] [Related]
57. Influence of antithrombin III on coagulation and inflammation in porcine septic shock.
Dickneite G; Leithäuser B
Arterioscler Thromb Vasc Biol; 1999 Jun; 19(6):1566-72. PubMed ID: 10364091
[TBL] [Abstract][Full Text] [Related]
58. Antithrombin III deficiency: clinical relevance and replacement therapy.
Gallus AS
Dev Biol Stand; 1987; 67():59-66. PubMed ID: 3609485
[TBL] [Abstract][Full Text] [Related]
59. Therapeutic use of antithrombin concentrate in sepsis.
Balk R; Emerson T; Fourrier F; Kruse JA; Mammen EF; Schuster HP; Vinazzer H
Semin Thromb Hemost; 1998; 24(2):183-94. PubMed ID: 9579641
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of coronary restenosis by antithrombin III in atherosclerotic swine.
Ali MN; Mazur W; Kleiman NS; Rodgers GP; Abukhalil JM; French BA; Raizner AE
Coron Artery Dis; 1996 Nov; 7(11):851-61. PubMed ID: 8993944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
